About

Jamie C. Barner, Ph.D., FAACP, FAPhA, is a health outcomes researcher, Division Head, and Professor in the Health Outcomes Division at the College of Pharmacy. She earned her B.S. in Pharmacy from The University of Texas at Austin and completed both her M.S. and Ph.D. degrees in Pharmacy Administration at Purdue University. Her research focuses on understanding factors that impact healthcare utilization and costs, particularly examining medication utilization patterns such as adherence, persistence, and switching, and their effects on health-related outcomes like emergency department visits and hospitalizations. She utilizes real-world data, including large claims databases, and employs advanced statistical methods to address these issues. Additionally, Dr. Barner investigates novel approaches to pharmacist services and their impact on patient outcomes, often using mixed methods that incorporate both qualitative and quantitative data involving patients and pharmacists. Her work emphasizes health disparities, especially among diverse and marginalized populations, with a focus on disease states associated with significant disparities such as sickle cell disease, diabetes, maternal health, and mental health. Most of her studies utilize Texas Medicaid data and settings like federally qualified health centers, contributing valuable insights into healthcare delivery and outcomes for underserved populations.

Research topics

• Computer Science
• Political Science
• Computer Security
• Internet privacy
• Business
• Medicine
• Artificial Intelligence
• Data science
• Endocrinology
• Demography
• Actuarial science
• Environmental health
• Finance
• Pharmacology
• Law
• Internal medicine

Selected publications

• Prevalence of mental health conditions among individuals with sickle cell disease in Texas Medicaid

  Figshare · 2026-02-21

  articleOpen access

  While individuals with sickle cell disease (SCD) experience mental health conditions (MHCs) that may negatively impact health outcomes, studies estimating the prevalence of MHCs in this population are limited. A retrospective analysis of Texas Medicaid data from 01/01/2016–05/31/2021 included individuals aged 3–63 years with SCD and continuously enrolled for one year. Study objectives were addressed using descriptive and bivariate analyses. Of the 2,878 (mean age = 23.1 ± 14.0) individuals included, 29.9% had at least one MHC. The most common MHCs were substance use disorders (15.4%), depressive disorders (8.4%), anxiety (8.3%), and suicidal ideation (6.1%). While no significant difference in age, those with SCD+MHCs had a significantly higher proportion of males (37.1% vs 27.7%, <i>p</i> &lt; 0.0001). Also, compared to those without MHCs, those with MHCs had a significantly (<i>p</i> &lt; 0.0001) higher mean number and proportion, respectively, of vaso-occlusive crises (5.8 ± 5.8 vs. 1.8 ± 3.1; 82.9% vs. 51.9%), SCD-related complications (3.3 ± 2.3 vs. 1.9 ± 1.8; 92.2% vs. 75.5%), and comorbid medical conditions (1.2 ± 1.2 vs. 0.5 ± 0.9; 65.5% vs. 35.7%). Individuals with SCD+MHCs had poorer health outcomes. Timely screening and treatment of MHCs and incorporating mental health specialists into the care team may improve patient outcomes. Interpretation should consider limitations inherent to claims data.

  PublisherDOI

• Prevalence of mental health conditions among individuals with sickle cell disease in Texas medicaid

  Figshare · 2026-02-21

  articleOpen access

  While individuals with sickle cell disease (SCD) experience mental health conditions (MHCs) that may negatively impact health outcomes, studies estimating the prevalence of MHCs in this population are limited. A retrospective analysis of Texas Medicaid data from 01/01/2016-05/31/2021 included individuals aged 3-63 years with SCD and continuously enrolled for one year. Study objectives were addressed using descriptive and bivariate analyses. Of the 2878 (mean age = 23.1 ± 14.0) individuals included, 29.9% had at least one MHC. The most common MHCs were substance use disorders (15.4%), depressive disorders (8.4%), anxiety (8.3%), and suicidal ideation (6.1%). While no significant difference in age, those with SCD+MHCs had a significantly higher proportion of males (37.1% vs 27.7%, <i>p</i> &lt; 0.0001). Also, compared to those without MHCs, those with MHCs had a significantly (<i>p</i> &lt; 0.0001) higher mean number and proportion, respectively, of vaso-occlusive crises (5.8 ± 5.8 vs. 1.8 ± 3.1; 82.9% vs. 51.9%), SCD-related complications (3.3 ± 2.3 vs. 1.9 ± 1.8; 92.2% vs. 75.5%), and comorbid medical conditions (1.2 ± 1.2 vs. 0.5 ± 0.9; 65.5% vs. 35.7%). Individuals with SCD+MHCs had poorer health outcomes. Timely screening and treatment of MHCs and incorporating mental health specialists into the care team may improve patient outcomes. Interpretation should consider limitations inherent to claims data.

  PublisherDOI

• Beliefs Regarding Patient Experience in the Emergency Department Among Individuals With Sickle Cell Disease

  Patient Experience Journal · 2026-04-29

  articleOpen access
  PublisherDOI

• Alcohol Use Disorder Diagnoses and HIV Preexposure Prophylaxis Adherence and Continuation: a Retrospective Cohort Study

  Journal of General Internal Medicine · 2026-01-27 · 1 citations

  articleOpen accessSenior author

  IMPORTANCE: Alcohol use disorder (AUD) has been associated with reduced adherence to and discontinuation of HIV preexposure prophylaxis (PrEP), potentially compromising its effectiveness. OBJECTIVE: This study examines the relationship between AUD and PrEP adherence and continuation. DESIGN: Retrospective cohort study using MarketScan Commercial Claims data. PARTICIPANTS: We included individuals aged 16-64 who initiated PrEP between January 1, 2014, and December 31, 2021, and had continuous insurance coverage. MAIN MEASURES: AUD diagnosis was identified within six months before PrEP initiation. Adherence was measured using the proportion of days covered (PDC) over 180 days and categorized by clinically relevant thresholds (≥ 85%, ≥ 80%, ≥ 57%). Continuation was assessed based on uninterrupted PrEP supply without a ≥ 30-day gap. Statistical analyses included propensity-score matching and regression modeling. KEY RESULTS: Among 43,913 eligible individuals, 1,245 (2.84%) had an AUD diagnosis prior to PrEP initiation. In a matched sample of 1,153 individuals, those with AUD had lower mean PDC (59.54% [34.14] vs. 65.85% [33.18]; p < 0.001) and fewer mean days of continuous PrEP use (107 [67.20] days vs. 119.90 [65.21] days; p < 0.001) compared to the Without AUD group. Regression analyses showed individuals with AUD had 6.31% lower mean PDC (95% CI: -9.05% to -3.57%; p < 0.001) and 12.93 fewer days of PrEP continuity (95% CI: -18.34 to -7.52 days; p < 0.001) compared to the Without AUD group. Findings may not be generalizable beyond commercially insured individuals, and we may have not captured all factors that influence PrEP adherence. CONCLUSION: Individuals with AUD before PrEP initiation exhibited lower adherence and continuation compared to those without AUD. Targeted interventions may be required to enhance PrEP adherence and continuity in this population.

  PublisherOA PDFDOI

• Prevalence of mental health conditions among individuals with sickle cell disease in Texas Medicaid

  Expert Review of Hematology · 2026-02-21

  articleCorresponding

  BACKGROUND: While individuals with sickle cell disease (SCD) experience mental health conditions (MHCs) that may negatively impact health outcomes, studies estimating the prevalence of MHCs in this population are limited. RESEARCH DESIGN AND METHODS: A retrospective analysis of Texas Medicaid data from 01/01/2016-05/31/2021 included individuals aged 3-63 years with SCD and continuously enrolled for one year. Study objectives were addressed using descriptive and bivariate analyses. RESULTS: < 0.0001) higher mean number and proportion, respectively, of vaso-occlusive crises (5.8 ± 5.8 vs. 1.8 ± 3.1; 82.9% vs. 51.9%), SCD-related complications (3.3 ± 2.3 vs. 1.9 ± 1.8; 92.2% vs. 75.5%), and comorbid medical conditions (1.2 ± 1.2 vs. 0.5 ± 0.9; 65.5% vs. 35.7%). CONCLUSIONS: Individuals with SCD+MHCs had poorer health outcomes. Timely screening and treatment of MHCs and incorporating mental health specialists into the care team may improve patient outcomes. Interpretation should consider limitations inherent to claims data.

  PublisherDOI

• HSD34 Telehealth for Disease Management: A Scoping Review of Effectiveness in the Perinatal Period

  Value in Health · 2025-07-01

  reviewSenior author
  PublisherDOI

• Predisposing, Enabling, and Need Factors Associated with Postpartum Depression Treatment Among Women Enrolled in Texas Medicaid

  Maternal and Child Health Journal · 2025-07-17

  article
  PublisherDOI

• Association between comorbid depression and antidepressant adherence with adherence to disease-modifying therapies in patients with sickle cell disease in Texas Medicaid

  Blood · 2025-11-03

  article

  Abstract Introduction: Depression is a prevalent mental health condition among patients with sickle cell disease (SCD) and is associated with poor clinical outcomes. The purpose of this study was to determine if comorbid depression and antidepressant adherence are related to adherence to disease-modifying therapies (DMTs) among patients with SCD. Methods: A retrospective analysis of Texas Medicaid data from 01/01/2016 to 08/31/2023 included patients who: had ≥3 medical claims for SCD, had ≥1 prescription claim for an SCD DMT, were aged 8-63 years, and were continuously enrolled for 6 months before and 12 months after the index date (first claim for an SCD DMT). In addition to the above, patients with SCD and comorbid depression had ≥1 medical claim for a depressive disorder, and patients with SCD and comorbid depression with treatment had ≥1 prescription claim for a selective serotonin reuptake inhibitor (SSRI) or serotonin norepinephrine reuptake inhibitor (SNRI). Proportion of days covered (PDC) was used to estimate adherence. Inferential statistics and logistic regression were used. Results: Of the 1,005 patients (mean age = 22.9±11.7, 52.4% female) included, 35.3% had depression, while 37.7% had anxiety. Compared to patients with SCD only, patients with SCD and comorbid depression were significantly older (20.4±11.3 vs. 27.4±10.9), with adults aged 27-34 having the highest prevalence of depression (22.8%), and a higher proportion were female (64.5% vs. 46.5%). Compared to patients with SCD only, patients with SCD and comorbid depression had a significantly higher mean number of SCD-related complications (1.5±1.5 vs. 2.2±1.7), vaso-occlusive crisis (VOC) events (1.5±2.3 vs. 2.8±3.0), SCD-related hospitalizations (0.2±0.7 vs. 0.5±1.5), and non-SCD-related comorbid medical conditions (0.4±0.8 vs. 0.9±1.1) in the pre-index period. Additionally, patients with SCD and comorbid depression had a significantly higher proportion of patients with a diagnosis of anxiety (76.6% vs. 16.5%) and serious mental health conditions (31.8% vs. 4.0%) during the study period. Among patients with SCD, mean adherence for each SCD DMT was: 38.7±26.7% (hydroxyurea), 37.5±29.5% (L-glutamine), 33.9±30.4% (crizanlizumab), and 60.9±34.1% (voxelotor). Proportion of patients taking hydroxyurea who were adherent (PDC≥80%) was 11.0%, and overall adherence to SCD DMTs was suboptimal (11.7%). In the unadjusted analysis, compared to adherent patients, a significantly higher proportion of non-adherent patients had comorbid depression (22.9% vs. 37.0%) and anxiety (24.6% vs. 39.5%). Compared to adherent patients, non-adherent patients were approximately 5 years older, and adolescents aged 10-15 comprised the highest proportion of adherent patients (45.8%), while young adults aged 22-26 were the lowest (&amp;lt;3%). The proportion of adherent patients was highest among patients with an index year of 2020 (31.3%). Compared to adherent patients, non-adherent patients had significantly higher numbers of SCD-related complications (1.1±1.5 vs.1.9±1.6) and VOC events (0.8±1.4 vs. 2.1±2.7). After adjustment, increasing number of VOC events (OR = 0.763; 95% CI: 0.642-0.907) in the pre-index period was associated with a lower odds of being adherent to SCD DMTs among patients with SCD. Among patients with SCD and comorbid depression with treatment, mean adherence to SSRIs and SNRIs was 43.2±29.1% and 42.3±30.8%, respectively. Overall mean adherence to antidepressants was 43.3±29.8%, and 20.5% (PDC≥80%) and 23.5% (PDC≥70%) of patients were adherent. After adjustment, antidepressant-adherent (PDC≥70%) patients had higher odds of adhering to SCD DMTs (PDC≥70%) (OR = 16.699; 95% CI: 3.966-70.309). After adjustment, increasing age and number of VOC events in the pre-index period were associated with a lower odds of being adherent to SCD DMTs. In addition, an increasing number of SCD-related complications in the pre-index period was associated with a higher odds of being adherent to SCD DMTs among patients with SCD and comorbid depression with treatment. Conclusion: The prevalence of depression among patients with SCD is high and associated with lower adherence to SCD DMTs. Antidepressant-adherent patients were more likely to adhere to SCD DMTs. SCD providers should regularly screen for depression, initiate depression treatment when appropriate, and encourage adherence to antidepressants, as this may improve adherence to SCD DMTs and overall health outcomes for this population.

  PublisherDOI

• Do Long-Acting Injectable Antipsychotics Prevent or Delay Hospital Readmission?

  Psychopharmacology Bulletin · 2025-08-12 · 9 citations

  articleOpen accessSenior author

  Introduction: Long-acting injectable (LAI) antipsychotics were developed as a way to decrease pill burden and simplify medication regimens by allowing less frequent administration to assist with medication adherence. Methods: The purpose of this study was to determine whether LAI antipsychotics prevent or delay hospital readmission in patients with a known history of medication non-adherence. The study is a retrospective evaluation of 240 men and women 18-65 years of age diagnosed with bipolar disorder, schizophrenia, or schizoaffective disorder discharged from an inpatient state hospital over a 2 year period of time on a LAI antipsychotic (fluphenazine LAI, haloperidol LAI, risperidone LAI or paliperidone LAI) or oral antipsychotic. Patients on LAIs were matched to patients on an equivalent oral dose, psychiatric diagnosis, number of prior hospital admissions, and length of stay. Results: Those who received a LAI (N = 120) had a significantly longer survival time (mean 278.0 days) without readmission compared to those who did not (N = 120; mean 243.6 days). There was no statistically significant difference in the frequency of one-year readmission between those who did receive a LAI (43.1%) and those who did not (56.9%). Those who received a LAI with administration frequency of a month or longer had a significantly longer survival time without readmission (mean 307.9 days) when compared to those with a shorter administration frequency (mean 245.0 days). Conclusion: This study revealed the use of LAI antipsychotics in those with a history of medication non-adherence, particularly those with longer administration frequency, have potentially promising outcomes.

  PublisherOA PDFDOI

• 1062 Reported experiences and perceptions of gender inequity among pharmacy faculty in the United States

  Journal of the American Pharmacists Association · 2025-09-01

  article
  PublisherDOI

Frequent coauthors

• Kenneth A. Lawson

  83 shared

• Karen L. Rascati

  The University of Texas at Austin

  81 shared

• Carolyn M. Brown

  The University of Texas at Austin

  72 shared

• Kristin M. Richards

  The University of Texas at Austin

  40 shared

• Lisa M. Mican

  33 shared

• Hyeun Ah Kang

  28 shared

• Leticia R. Moczygemba

  The University of Texas at Austin

  26 shared

• Marc L. Fleming

  25 shared

Labs

• Health Outcomes DivisionPI

Awards & honors

• Southwestern Drug Corporation Centennial Endowed Fellow in P…
• Graduate Mentor of the Year Award